SIGHT — Gensight Biologics SA Share News
0.000.00%
Last trade - 00:00- €17.21m
- €28.38m
- €0.00m
Brief: Gensight Biologics Appoints Laurence Rodriguez As Chief Executive Officer
Brief: Gensight Biologics: Launch Of Offering For Indicative Amount Of EUR 5 Million
Brief: Gensight Biologics: Preliminary Assay Indicating Successful Manufacture Of Second LUMEVOQ GMP Batch
Brief: Gensight Biologics End-Sept Cash Position 2.4 Million Euros
Brief: GenSight Biologics Provides Update On European Medicines Agency Scientific Advice For LUMEVOQ®
Brief: GenSight Biologics H1 Operating Income Down At EUR 2.7 Mln
Brief: GenSight Biologics Obtains Funding Of EUR 10 Million From Sofinnova Partners, Invus And UPMC Enterprises
Brief: Gensight Biologics Says Cash Runway Extended To End Of July, Interim Financial Statement Postponed
Brief: GenSight Biologics: Re-approval of FY 2022 Consolidated Financial Statements
Brief: Gensight Biologics Announces The Re-Approval Of Its Full Year 2022 Consolidated Financial Statements
Brief: EMA Says Application For Marketing Authorisation For The Advanced Therapy Medicinal Product Lumevoq Withdrawn
Brief: Gensight Biologics SA Says Taking Additional Measures To Reduce Operating Cash Burn In 2023
Brief: GenSight Biologics Withdraws Its EMA Application For LUMEVOQ®
Brief: Gensight Biologics Cash Runway Confirmed To June 2023
Brief: Gensight Biologics Confirms Efficacy And Safety Results At 3 Years In Reflect Phase III Clinical Trial With Lumevoq®
Brief: Gensight Biologics Announces Publication Of LUMEVOQ Safety Data
Brief: Gensight Expects To Start LUMEVOQ PPQ Campaign In May
Brief: Gensight Biologics: 1 Year Safety Data And Efficacy Signals From Phase I/Ii Trial Of GS030
Brief: Gensight Biologics End-Dec Cash Position At EUR 10.6 Mln